Type 2 Diabetes. Diabetes mellitus due to underlying condition
Conditions
Interventions
Intervention 1: Intervention group: Participants in this group will take one tablet containing 1000 mg of vitamin C (ascorbic acid) daily for 4 consecutive weeks. The tablets will be taken orally, pre
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Diagnosis of Type 2 Diabetes according to ADA criteria (HbA1c = 7% or fasting glucose = 126 mg/dL). No intake of antioxidant or vitamin supplements in the past 3 months. Stability of diabetes management medication regimen in the past month. No acute infectious or inflammatory diseases in the past month. No chronic infectious or inflammatory diseases. A minimum of one-year disease history since onset. No smoking or use of tobacco products. No history of liver or kidney diseases, autoimmune or chronic inflammatory diseases, blood disorders, hypothyroidism or hyperthyroidism, myocardial infarction, or intake of diuretics and other drugs containing vitamin C; no use of antimicrobial mouthwashes, anti-inflammatory drugs, or antibiotics in the past 3 months. Provision of informed consent to participate in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum levels of the inflammatory marker CRP. Timepoint: Once before the intervention and once after the intervention. Method of measurement: From the intervention group, two 5-mL blood samples will be collected, and from the control group, only one 5-mL blood sample will be taken from the antecubital vein into tubes containing a separation gel and without anticoagulant, after 8 to 12 hours of fasting (once at the beginning of the study and once at the end of the fourth week). The samples will be immediately transferred to the laboratory, centrifuged, and serum separated. They will then be stored at -20°C until analysis. Serum CRP levels will be measured using the ELISA method with commercially available validated kits, following the manufacturer’s instructions. | — |
Secondary
| Measure | Time frame |
|---|---|
| Metabolic indices: including fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c). Timepoint: Once before the intervention and once after the intervention. Method of measurement: Fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) will be measured using commercially available validated kits, following the manufacturer’s instructions. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmin Yadegari
Birjand University of Medical Sciences
Outcome results
None listed